What peripheral neuropathy complications are associated with the ABVD regimen (Adriamycin/doxorubicin, Bleomycin, Vinblastine, Dacarbazine)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 17, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Peripheral Neuropathy Complications from ABVD Chemotherapy

Vinblastine is the primary neurotoxic agent in ABVD, causing peripheral neuropathy in a dose-dependent manner, predominantly affecting sensory nerves with small fiber involvement that manifests as burning pain, paresthesias, and autonomic dysfunction. 1, 2

Primary Neurotoxic Agent and Mechanism

Vinblastine (the "V" in ABVD) is a vinca alkaloid that causes small fiber neuropathy through disruption of microtubule function in peripheral nerves. 1 The drug affects nerve terminals involved in temperature and pain perception, leading to:

  • Sensory neuronopathy (ganglionopathy) due to damage of dorsal root ganglion cell bodies, which lack adequate blood-brain barrier protection and are therefore vulnerable to irreversible neurotoxic damage 1
  • Length-dependent axonal neuropathy affecting distal nerves first in a "dying back" pattern 1

Clinical Manifestations

Sensory Symptoms (Most Common)

"Plus" symptoms:

  • Burning sensation in feet and hands (hallmark of small fiber neuropathy) 1
  • Acral pain and paresthesias (tingling, "pins and needles") 1
  • Lancinating pain potentiated by pin-prick testing 1
  • Dysesthesia, allodynia, and hyperalgesia 1

"Minus" symptoms:

  • Numbness in glove-and-stocking distribution 1
  • Impaired light touch, vibration sense, and proprioception 1
  • Decreased pain and temperature sensation in affected areas 1

Motor Involvement (Less Common)

  • Numbness of digits (most frequent motor manifestation) 2
  • Loss of deep tendon reflexes 2
  • Distal weakness and atrophy of small foot muscles 1
  • Peripheral neuritis 2
  • Tremor and cramps 1

Autonomic Dysfunction

Vinblastine-induced small fiber damage causes autonomic involvement including: 1

  • Constipation (most common)
  • Abdominal pain
  • Postural hypotension
  • Bladder disturbances
  • Delayed gastric emptying
  • Reduced heart rate variability

Rare Neurological Complications

  • Mental depression 2
  • Headache 2
  • Convulsions 2
  • Vestibular and auditory damage (eighth cranial nerve): partial or total deafness (temporary or permanent), dizziness, nystagmus, vertigo 2

Doxorubicin Contribution

While vinblastine is the primary culprit, doxorubicin (Adriamycin) can cause peripheral sensory and motor neuropathy, though this is less common than its cardiac toxicity. 3 The combination may have additive neurotoxic effects.

Critical Clinical Pitfalls

Drug Interaction Warning

Severe, excessive neurotoxicity occurs when ABVD is combined with ritonavir-boosted protease inhibitors (used in HIV treatment). 4 Ritonavir inhibits CYP3A4, which metabolizes vinblastine, leading to dramatically increased vinblastine concentrations and severe neuropathy. This is particularly relevant as Hodgkin lymphoma is the second most common non-AIDS-defining malignancy in HIV-positive patients. 4

Timing and Progression

  • Symptoms typically occur within the first 2 months of treatment 1
  • Progress during active treatment 1
  • Usually stabilize after treatment completion 1
  • Neurotoxicity may be irreversible, particularly with ganglionopathy 1

Assessment Requirements

Baseline and pre-cycle clinical evaluation is critical to detect neuropathy before it becomes irreversible. 1 Look specifically for:

  • Distal sensory changes (light touch, vibration, pin-prick, temperature)
  • Deep tendon reflexes
  • Motor strength in distal muscles
  • Autonomic symptoms (constipation, orthostatic symptoms)
  • Gait and balance abnormalities

Asymmetric Presentation

The clinical picture may be asymmetrical, particularly with ganglionopathy, and predominantly involves proprioception but does not exclude motor involvement. 1 This asymmetry should prompt consideration of pre-existing neurological conditions like Charcot-Marie-Tooth disease. 1

Management Implications

Early detection through ongoing assessment before every cycle enables intervention before neuropathy becomes irreversible. 1 Conventional nerve conduction studies often do not mirror patients' symptoms and show only modest improvement despite clinical recovery, so clinical assessment takes precedence over electrophysiology. 1

Neurophysiology should be considered when:

  • Asymmetric symptom pattern exists 1
  • Normal clinical examination despite patient complaints 1
  • Severe neurotoxicity with motor involvement occurs (to rule out predisposing conditions) 1

Note: Small fiber neuropathy may present with normal conventional neurophysiology. 1

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.